Humatech Aktie

Humatech ROE

ROE (Return on Equity) for Humatech (HUMT) pr. 6. mar. 2026 udgør 0,48.

ROE

0,48

Sidst opdateret: 6. mar. 2026

I 2026 var egenkapitalrentabiliteten (ROE) for Humatech 0,48, en stigning på % sammenlignet med 0 ROE i det foregående år.
API Docs Get API Key

Humatech Aktieanalyse

Hvad gør Humatech? Humatech Inc is an international company that specializes in the development, production, and marketing of products for the healthcare industry. The company was founded in 1983 and has since adapted its business models and strategies to meet the changing demands of the market. It is now headquartered in Virginia, USA and operates on multiple continents. The business model of Humatech Inc focuses on the manufacturing of diagnostic and testing products for laboratory and clinical facilities. These products are designed for the diagnosis of diseases such as cancer, diabetes, pregnancy, thyroid problems, and many others. The company also offers HIV, hepatitis, and troponin tests. The high quality of these products has helped the company establish strong brand recognition and customer loyalty. In addition to its products, Humatech Inc also provides services in various areas to offer comprehensive solutions tailored to individual needs. These services include consulting, software solutions, and training, contributing to optimized and efficient operations in medical facilities and laboratories. The different divisions of Humatech Inc encompass a wide range of products and services. The category of diagnostic and testing products forms the core of the company, including tests for diabetes, pregnancy, thyroid problems, cancer, HIV, and hepatitis. The range also includes specialized tests for kidney problems and heart diseases. The company is constantly striving to expand its range of tests for new health issues. Under the category of consulting services, Humatech Inc offers in-depth knowledge of current medical developments, diagnostic procedures, and testing methods. Customers can choose from a wide range of services, including the development of specific test procedures, marketing support, and workflow optimization. The "software solutions" business field includes a variety of online tools to support diagnostic procedures and tests. The software allows medical facilities and laboratories to automate their workflow, manage and analyze data, and quickly retrieve test results. To provide customers with added value, Humatech Inc also offers a range of training programs. These not only cover the operation and application of the products, but also teach optimal work and result processes. Overall, Humatech Inc is an important player in the healthcare industry. By focusing on the development and marketing of diagnostic and testing products, the company is able to sustainably convince its customers through high product quality and services. The wide product range, services, and extensive network of employees, consultants, and customers make the company a forward-thinking service provider. Humatech er en af de mest populære virksomheder på Eulerpool.com.

ROE i detaljen

Afkodning af egenkapitalforrentningen (ROE) for Humatech

Egenkapitalforrentningen (ROE) for Humatech er en grundlæggende finansiel nøgletal, der vurderer selskabets rentabilitet i forhold til egenkapitalen. ROE, som beregnes ved at dividere nettoindtjeningen med aktionærernes egenkapital, illustrerer, hvor effektivt selskabet genererer overskud på aktionærernes investeringer. En højere ROE indikerer øget effektivitet og profitabilitet.

År-til-år Sammenligning

Analyse af Humatech's ROE på årsbasis hjælper med at følge rentabilitetstrends og den finansielle performance. En stigende ROE indikerer en forbedret rentabilitet og værdiskabelse for aktionærerne, mens en faldende ROE kan tyde på problemer med at generere overskud eller med håndteringen af egenkapitalen.

Effekter på Investeringer

ROE for Humatech er afgørende for investorer, der vurderer selskabets rentabilitet, effektivitet og investeringsattraktivitet. En robust ROE angiver selskabets evne til at omdanne egenkapitalinvesteringer til overskud og øger dermed dens tiltrækningskraft for potentielle og nuværende investorer.

Fortolkning af ROE-udsving

Ændringer i Humatech's ROE kan skyldes svingninger i nettoindtjeningen, egenkapitalen eller begge dele. Disse svingninger bliver undersøgt for at vurdere ledelseseffektiviteten, de finansielle strategier samt de forbundne risici og muligheder, og hjælpe investorer med at træffe velinformerede beslutninger.

Ofte stillede spørgsmål om Humatech aktien

ROE (Return on Equity) af Humatech var 0 0,48

Profitability — Humatech

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets
Aktiespareplaner tilbyder en attraktiv mulighed for investorer at opbygge formue på lang sigt. En af de største fordele er den såkaldte cost-average-effekt: Ved regelmæssigt at investere et fast beløb i aktier eller aktiefonde, køber man automatisk flere andele, når priserne er lave, og færre, når de er høje. Dette kan føre til en mere fordelagtig gennemsnitspris per andel over tid. Desuden giver aktiespareplaner også småinvestorer adgang til dyre aktier, da de kan deltage med små beløb. Den regelmæssige investering fremmer også en disciplineret investeringsstrategi og hjælper med at undgå følelsesladede beslutninger, som impulsiv køb eller salg. Derudover drager investorer fordel af den potentielle værdistigning af aktierne samt af udbytteudlodninger, der kan geninvesteres, hvilket forstærker renters rente effekten og dermed væksten af det investerede kapital.

All Key Metrics — Humatech